GlassScriptPhysician profile
Jennifer L Conran
NPI 1689113797
$3,591.88
in general payments reported to CMS, 2019-2025
31 companies · $37.80 in 2025
The $37.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,430 · 2022: $1,410 · 2023: $676 · 2024: $37.88 · 2025: $37.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.98 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $278.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.14 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $259.63 | 2021-2022 | |
| Pfizer INC. | $249.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $227.75 | 2021-2023 | Trelegy Ellipta |
| Ucb, INC. | $167.40 | 2021-2023 | Briviact, Nayzilam |
| Astrazeneca Pharmaceuticals LP | $123.31 | 2021-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $120.04 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.23 | 2022-2023 | |
| Radius Health, INC. | $108.12 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $82.11 | 2021-2022 | |
| Lilly USA, LLC | $79.32 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Dexcom, INC. | $75.76 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.38 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $71.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.86 | 2021-2022 | |
| Abbott Laboratories | $58.20 | 2021-2022 | |
| Esperion Therapeutics, INC. | $45.93 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.31 | 2023 | Ajovy, Austedo Xr |
| Advanced Respiratory, INC | $29.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.74 | 2021 | |
| Mylan Specialty L.P. | $22.45 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.71 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.13 | 2023 | Quviviq |
| Amgen INC. | $19.06 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.85 | 2021 | |
| Astellas Pharma US INC | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Conran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.